Edition:
United States

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

36.49USD
22 Nov 2017
Change (% chg)

$-0.41 (-1.11%)
Prev Close
$36.90
Open
$37.05
Day's High
$37.60
Day's Low
$36.47
Volume
87,409
Avg. Vol
136,865
52-wk High
$40.35
52-wk Low
$23.07

Latest Key Developments (Source: Significant Developments)

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces pricing of public offering of common stock
Wednesday, 20 Sep 2017 08:31pm EDT 

Sept 20 (Reuters) - Acceleron Pharma Inc :Acceleron announces pricing of public offering of common stock.Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share.  Full Article

Acceleron announces proposed public offering of common stock
Tuesday, 19 Sep 2017 04:12pm EDT 

Sept 19 (Reuters) - Acceleron Pharma Inc :Acceleron announces proposed public offering of common stock.Acceleron Pharma Inc - Announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock.Acceleron Pharma - Intends to use net proceeds from offering to conduct clinical trials and associated activities.  Full Article

Acceleron Pharma Q2 loss per share $0.77
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports second quarter 2017 operational and financial results.Qtrly loss per share $0.77.Acceleron Pharma Inc - collaboration revenue for Q2 was $3.1 million..  Full Article

Acceleron announces first patient treated in phase 2 clinical trial of ACE-083
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Acceleron Pharma Inc :Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease.  Full Article

Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
Thursday, 1 Jun 2017 07:30am EDT 

June 1 (Reuters) - Celgene Corp :Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia.Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​.Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​.Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​.  Full Article

Acceleron Pharma qtrly loss per share $0.66
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Acceleron Pharma Inc :Acceleron pharma reports first quarter 2017 operational and financial results.Acceleron pharma inc - collaboration revenue for q1 was $3.7 million.Acceleron pharma inc qtrly loss per share $0.66.Acceleron pharma inc - plans to initiate luspatercept phase 3 trial in first-line, lower-risk mds in early 2018.  Full Article

Acceleron announces management change
Tuesday, 2 May 2017 04:30pm EDT 

May 2 (Reuters) - Acceleron Pharma Inc ::Acceleron announces management change.Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer.Acceleron Pharma Inc - Ertel was recently diagnosed with amyotrophic lateral sclerosis.  Full Article

Acceleron says enrolment for late stage studies now expected to be completed in Q2
Thursday, 27 Apr 2017 07:35am EDT 

April 27 (Reuters) - Acceleron Pharma Inc :Acceleron provides clinical development updates on luspatercept program.Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017."we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018".Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept.New phase 3 trial of luspatercept is expected to be initiated in early 2018.  Full Article

Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease
Thursday, 16 Mar 2017 07:00am EDT 

Acceleron Pharma Inc - : Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar .Second phase 2 study for ACE-083 expected to begin 2H 2017.  Full Article

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions